Nektar Therapeutics
NKTR
379 hedge funds and large institutions have $7.83B invested in Nektar Therapeutics in 2018 Q2 according to their latest regulatory filings, with 99 funds opening new positions, 128 increasing their positions, 128 reducing their positions, and 74 closing their positions.
34% more first-time investments, than exits
New positions opened: 99 | Existing positions closed: 74
20% more call options, than puts
Call options by funds: $231M | Put options by funds: $193M
6% more funds holding
Funds holding: 359 → 379 (+20)
0% more repeat investments, than reductions
Existing positions increased: 128 | Existing positions reduced: 128
0.27% less ownership
Funds ownership: 6.51% → 6.24% (-0.27%)
53% less capital invested
Capital invested by funds: $16.7B → $7.83B (-$8.84B)
67% less funds holding in top 10
Funds holding in top 10: 18 → 6 (-12)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$257M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$124M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$79.4M |
| 4 |
JP Morgan Chase
New York
|
+$67.1M |
| 5 |
O
OppenheimerFunds
New York
|
+$65M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$139M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$130M |
| 3 |
DFO
Duquesne Family Office
New York
|
-$127M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$94.9M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$81.7M |
NKTR Hedge Fund Activity: Q2 2018 in Review
379 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q2 2018, worth a combined $7.83B — down 53% from $16.7B a quarter earlier.
Buyers outnumbered sellers: 99 funds opened new NKTR positions and 74 closed out — a net gain of 25 holders — while 128 added to existing stakes and 128 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $257M. The largest seller was BlackRock, cutting an estimated $139M.
- 379 institutional investors held Nektar Therapeutics (NKTR) as of Q2 2018, up from 359 in Q1 2018.
- Funds reported $7.83B of Nektar Therapeutics stock for Q2 2018, down 53% quarter-over-quarter.
- 99 funds opened new Nektar Therapeutics positions in Q2 2018 and 74 closed out, a net change of +25 holders.
- The largest Nektar Therapeutics buyer in Q2 2018 was Wellington Management Group, an estimated $257M added.
- The largest Nektar Therapeutics seller in Q2 2018 was BlackRock, an estimated $139M sold.
Based on aggregated 13F filings for Q2 2018.